Shots:
- Ascletis Pharma reported that the first participants have been dosed in a US 13-week P-II study of ASC30, an oral small-molecule GLP-1 receptor agonist, for the treatment of type 2 diabetes mellitus, with topline data expected in Q3’26
- The study will enroll ~100 pts and evaluate ASC30’s effects on HbA1c as a 1EP, and the 2EPs include fasting blood glucose, body weight, and safety; ASC30 will be administered QD with weekly dose titration from 1 mg to target doses of 40 mg, 60 mg and 80 mg
- ASC30 previously demonstrated weight loss of up to 5.4%, 7.0% and 7.7% for 20 mg, 40 mg and 60 mg, respectively in a completed US 13week P-II obesity study (n=125), with favorable GI tolerability and no hepatic safety signals, supporting its potential for oral GLP-1 profile
Ref: Ascletis Pharma | Image: Ascletis | Press Release
Related News: Ascletis Pharma Receives the US FDA IND Clearance to Initiate P-II Trial of ASC30 for Type 2 Diabetes
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
